Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm

Nurse Practitioner

Volumn 39, Issue 11, 2014, Pages 45-51

  Finks, Shannon W ^a   Campbell, Jennifer D ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Regional Medical Center Memphis   (United States)

Author keywords

Drug interactions; HMG CoA reductase inhibitors; Myopathy; Patient safety; Pharmacology; Rhabdomyolysis; Statins

Indexed keywords

CYTOCHROME P450 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

DRUG COMBINATION; DRUG INTERACTION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; PATIENT HARM; PRACTICE GUIDELINE; PREVENTION AND CONTROL; RISK ASSESSMENT; UNITED STATES;

CYTOCHROME P-450 ENZYME INHIBITORS; DRUG INTERACTIONS; DRUG LABELING; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT HARM; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SIMVASTATIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84920939045     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000443232.02852.f8     Document Type: Review

References (33)

1. The Use of Medicines in the United States: Review of 2010. Report by the IMS Institute for Healthcare Informatics. www.imshealth.com/imshealth/Global/Content/IMS%20Institute/Documents/IHII-UseOfMed-report%20.pdf.
2. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. Circulation. 2002;106(8):1024-1028.
3. FDA. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. June 8, 2001 [update December 15, 2011].
4. Frishman WH, Horn J. Statin-drug interactions: not a class effect. Cardiol Rev. 2008;16(4):205-212.
5. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy. 2006;26(11):1601-1607.
6. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4(suppl 7):13-53.
7. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6(11):904-916.
8. Mareedu RK, Modhia FM, Kanin EI, et al. Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. Prev Cardiol. 2009;12(2):88-94.
9. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553-564.
10. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16(12):873-879.
11. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol. 2004;94(7):935-938.
12. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs. 2004;4(5):281-297.
13. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005;96(9A):44K-49K.
14. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140-1146.
15. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95(1):120-122.
16. McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol. 2007;60(8):812-818.
17. Product information for Lipitor. Pfizer Inc., New York, NY 10017. 2012. www.lipitor.com.
18. Product information for Mevacor. Merck & Co., Inc. Whitehouse Statin, NJ 08889. 2012. http://www.merck.com/product/usa/pi-circulars/m/mevacor/mevacor-pi.pdf.
19. Product information for Zocor. Merck & Co, Inc. Whitehouse Statin, NJ 08889. 2012. http://www.merck.com/product/usa/pi-circulars/z/zocor/zocor-pi.pdf.
20. Product information for Lescol/Lescol XL. Novartis Pharmaceuticals Corporation. East Hanover, NJ 07936. 2012. http://www.pharma.us.novartis.com/product/pi/pdf/Lescol.pdf.
21. Product information for Crestor. AstraZeneca Pharmaceuticals LP. Wilmington, DE 19850. 2012. www.crestor.com.
22. Product information for Livalo. Kowa Pharmaceuticals America, Inc. Montgomery, AL 36117. 2012. www.livalorx.com.
23. Product information for Pravachol. Bristol-Myers Squibb Company. Princeton, NJ 08543. 2012. http://packageinserts.bms.com/pi/pi-pravachol.pdf.
24. Product Information for Tricor tablets, fenofibrate tablets. Abbott Laboratories, North Chicago, IL, 2004.
25. Product Information for gemfibrozil. Zydus Pharmaceuticals USA, Inc., Princeton, NJ, 2006.
26. Clinically significant statin drug interactions. Pharmacist's Letter/Prescriber's Letter 2009;25:250812.
27. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403-414.
28. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J. 2008;29(17):2083-2091.
29. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke. 2006;37(10):2640-2643.
30. Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med. 2004;164(19):2162-2168.
31. Gillett RC Jr, Norrell A. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am Fam Physician. 2011;83(6):711-716.
32. McKenney JM. An assessment of statin safety. Am J Manag Care. 2006;12(11 suppl):S310-S317.
33. McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C-94C.